Presentation at the Annual Meeting of the American College of Rheumatology (November 12, 2019; Atlanta, GA): A phase 2 double-blind clinical trial to examine the comparative effects on osteoarthritic knee pain of CGS-200- 1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)

Propella Therapeutics, Inc. presented “A phase 2 double-blind clinical trial to examine the comparative effects on osteoarthritic knee pain of CGS-200- 1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)” at the Annual Meeting of the American College of Rheumatology in Atlanta, GA on November 12, 2019.